American Diabetes Association’s 80th Annual Scientific Sessions: #ADA2020


From Friday, June 12 to Tuesday, June 16th, the biggest diabetes conference of the year took place virtually—the American Diabetes Association’s 80th Annual Scientific Sessions (#ADA2020). This annual meeting brought together researchers, healthcare providers, diabetes technology companies and many more from around the globe. Originally set in Chicago, the ADA announced the shift to an all digital experience in light of the COVID-19 pandemic.

During these five days, there were more than 1,800 posters, 800 original research presentations and 200 virtual sessions covering the latest advancements in research, treatment and care for people living with diabetes. That’s a lot of news to take in! Beyond Type 1 did the hard work for you: we reported live from ADA 2020 and aggregated the most important industry and technological updates here.

Explore our in-depth coverage

Preventing and Delaying Type 1 Diabetes: Updates From the Teplizumab Trial

Half of those treated with teplizumab remain diabetes-free, compared to 22% of those taking placebo, and the delay in diabetes onset was close to 3 years.MORE

Disparities in Diabetes and Diabetes Care—What Can We Do About It?

At this ADA 2020 session, systemic racism and implicit bias were clear contributors to poor health and healthcare outcomes for Black and Latinx communities.MORE

T1D Exchange + Beyond Type 1 Marathon Study Presented at ADA 2020

The Beyond Type Run team has taken on 26.2 miles to not only raise awareness and funds for T1D, but to provide crucial data for a study pertaining to management of Type 1 before, during, and after a m...MORE

One Drop Announces New Overnight Hypo Predictions and Long-Term Health Forecasts at ADA 2020

One Drop unveiled new AI-powered predictions for blood glucose, A1C, blood pressure, and weight up to six months in advanceMORE

FreeStyle Libre 2 Approved for Use in U.S.

Those living with type 1 diabetes in the U.S. now have the opportunity to manage their disease utilizing the perks of Abbott’s Freestyle Libre 2. MORE

How to Measure Success in Pediatric Diabetes Care

In a spirited debate, speakers made their case for whether the primary metric for pediatric diabetes success should be A1C or Time in Range (TIR).MORE

Nationwide Study in France Shows Dramatic Drop in DKA in Type 1 and Type 2 After Starting on FreeStyle Libre

The study included more that 70,000 patients living with diabetes and DKA rates were reduced by 52% for patients with T1D and 47% for patients with T2D.MORE

News From DiabetesMine™ D-Data ExChange 2020

D-Data began in 2013 as a spinoff of the DiabetesMine Innovation Summit, sparking the #WeAreNotWaiting movement + celebrating DIY patient entrepreneurship. MORE

Closed Loop Updates: Omnipod Horizon and Medtronic 780G data presented at ADA 2020

Data from four new clinical trials involving Hybrid Closed Loop systems, Medtronic 780G and Omnipod 5 Powered by Horizon was presented at ADA 2020.MORE

Check out our breaking news coverage

Breaking News From ADA 2020

New rapid-acting insulin Lyumjev from Lilly receives FDA approval for type 1 and type 2 diabetes, Abbott announced that the FDA has approved the FreeStyle Libre 2 System, One Drop unveiled new AI-powe...MORE

WRITTEN BY BT1 Editorial Team, POSTED 06/10/20, UPDATED 01/03/23

This piece was authored collaboratively by the Beyond Type 1 Editorial Team.